Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig plus chemotherapy versus durvalumab plus chemotherapy in advanced biliary tract cancer
NL-OMON61020Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Rilvegostomig plus chemotherapy with Durvalumab plus chemotherapy (2 arms). Primary endpoint: Overall survival. Started Apr 2026; status: recruiting.
02
Drugs
rilvegostomigdurvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NL-OMON61020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61020.